CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores a novel approach to cancer treatment by utilizing donor T cells that can recognize and attack cancer cells. By genetically modifying patient T cells with specific receptors from donor T cells, it aims to enhance the immune response against tumors, particularly in organs that can be replaced.
Despite recent advances in cancer immunotherapy, most patients with metastatic cancer are not cured.
Major reasons are lack of homogeneously and highly expressed molecules that can be safely targeted and evoke efficient T-cell responses. I propose that the strong T-cell responses leading to rejection of transplanted organs can be exploited to “reject” cancer by specific recognition of tissue-restricted targets.
To this end, I recently demonstrated that healthy donor blood provides a rich source…
UNIVERSITETET I OSLO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Norway, Oslo
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
